Verified Rigor RecordRigor Reviewed

Rigor-Reviewed Manuscript

A Perspective on the Emergence of Sialic Acids as Potent Determinants Affecting Leishmania Biology · 10.4061/2011/532106

Name: Verified Rigor Record — A Perspective on the Emergence of Sialic Acids as Potent Determinants Affecting Leishmania Biology · 10.4061/2011/532106
Item: A Perspective on the Emergence of Sialic Acids as Potent Determinants Affecting Leishmania Biology · 10.4061/2011/532106
Rating: 75
Author: Αlpha¹

Paper source

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · July 6, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

WARN

Warnings to address · review

Eight dimensions — click a segment for details

Critical

High-priority

Model-reported confidence: moderateReviewer agreement: lowEngine: 7.5.0Source: full text

Not verified in this report

References were not verified against Crossref/OpenAlex.
No reported statistical tests were found to recompute.

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a narrative review/perspective on sialic acids in Leishmania that effectively synthesizes prior work and establishes a clear scientific premise. The main methodological weaknesses are in the key resources (missing vendor/catalog numbers) and statistical analysis (threshold p-values, no effect sizes, test assumptions not verified), as well as reporting transparency (no review methodology/reporting guideline). No new experimental data are generated, so many design criteria are not applicable.

Three independent reviewers with different models (all AI) scored all eight dimensions; reviewers 1 and 3 agreed closely (scores 75 and 72, respectively) while reviewer 2 considered more dimensions not applicable, rating only scientific premise and reporting transparency as pass (score 100). This synthesis adopts the majority view that the experimental re-presentation elevates resource identification and statistical reporting requirements above a pure narrative review. The copyedit pass and verification components (statistics, reproducibility, integrity, claim audit) were also considered.

12 major claims checked against the paper's own evidence: all adequately supported.

2 integrity concerns flagged (0 high).

Rigor

Eight Dimensions1 pass · 3 warn

12 major claims5 partial7 supported

The introduction (Sections 1–4) comprehensively reviews the literature on Leishmania biology, glycoconjugates, and sialic acids in other parasites, establishing a strong rationale for exploring sialoglycobiology in Leishmania. Strengths and limitations of prior work are acknowledged (e.g., Section 4 notes the role of sialic acids in T. cruzi, P. falciparum). The authors explicitly state that 'sialoglycobiology is a less explored area in leishmaniasis' and link this gap to their study objectives. Hypotheses about 9-O-AcSA as a virulence marker emerge logically from the cited evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper clearly establishes the scientific foundation for studying sialic acids in Leishmania, citing prior work on glycoconjugates and the known roles of sialic acids in other parasites.

Evidence

direct quote[Sections 1–4]

“Already many parasite-surface glycoconjugates and other factors influencing parasite biology with or within the host cell are reported. Could we find many more? In spite of many potential roles of diverse forms of sialic acids in different cellular processes, sialoglycobiology is a less explored area in leishmaniasis.”

direct quote[Abstract]

“The present paper focuses on identification, characterization, and differential distribution of sialoglycotope having the linkage-specific 9-O-acetylated sialic acid in promastigotes of different Leishmania sp. ... asserting them to be important molecules influencing parasite biology.”

direct quote[Section 7]

“First of all, there are only a few lectins which can bind only to linkage-specific 9-O-AcSA. ... the labile nature of O-acetylation due to sensitivity towards alkaline pH and high temperature which are two main inherent problems also restricts the use of many other chemical/analytical methods for elaborate study.”

PASSReviewer 2· 95% conf

The scientific premise is well established through extensive citations of prior work on Leishmania glycobiology and sialic acid in other parasites, with a clear rationale linking sialoglycotopes to virulence.

Evidence

paraphrase[Sections 3, 4]

“Sections 3 and 4 discuss glycoconjugates in Leishmania and sialic acids in Trypanosoma, Plasmodium, Toxoplasma, citing multiple references.”

direct quote[Abstract, Introduction]

“Despite the steady progress in the field of parasite glycobiology, sialobiology has been a less traversed domain of research in leishmaniasis.”

paraphrase[Section 7, Critical Evaluation and Perspective]

“Section 7 lists limitations: few lectins for 9-O-AcSA, labile O-acetylation, lack of specific inhibitors.”

PASSReviewer 3· 90% conf

The paper establishes a clear scientific premise for studying sialic acids in Leishmania biology, citing prior work on glycoconjugates and sialic acids in parasites, and builds a logical rationale linking the gap in sialobiology research to the study's objectives.

Evidence

paraphrase[Sections 1, 3, 4]

“Sections 1, 3, and 4 extensively reference prior work on glycoconjugates (LPG, gp63, etc.) and sialic acids in Trypanosoma, Plasmodium, Entamoeba, Toxoplasma.”

direct quote[Section 1, paragraph 3]

“Could elucidation of sialoglycobiology save us from this grave situation? Hence, this review has made a modest attempt to assemble the observations on the sialobiology of Leishmania sp. highlighting their importance in leishmaniasis.”

direct quote[Section 7, paragraph 6]

“First of all, there are only a few lectins which can bind only to linkage-specific 9- O- AcSA. Achatinin-H, in spite of having a narrow binding specificity towards 9- O -AcSA derivatives α 2-6 linked to subterminal N -acetylgalactosamine (9- O -AcSA α 2-6GalNAc), binds only to the terminal modifications on glycoproteins”

The paper is a Perspective/Review summarizing published data, with no new experimental design elements such as randomization, blinding, power analysis, or inclusion/exclusion criteria. All sub-criteria are not applicable.

Sub-criteria

controlsN/A

power analysisN/A

blinding levelsN/A

outlier handlingN/A

randomization unitN/A

inclusion exclusionN/A

randomization methodN/A

replicate distinctionN/A

independent replicationN/A

Per reviewer (3) — the votes behind the verdict

N/AReviewer 1· 90% conf

This is a narrative review/perspective that integrates previously published experimental data from the authors' own work, not a new study with a defined experimental design.

Evidence

direct quote[Abstract]

“Hence, this review has made a modest attempt to assemble the observations on the sialobiology of Leishmania sp. highlighting their importance in leishmaniasis.”

N/AReviewer 2· 100% conf

This is a narrative review, not an interventional, observational, or computational study; no study design criteria apply.

Evidence

direct quote[Title, Abstract]

“A Perspective on the Emergence of Sialic Acids as Potent Determinants Affecting Leishmania Biology”

WARNReviewer 3· 85% conf

The paper primarily functions as a review and reports prior experimental findings without full methodological details. Key design elements (blinding, randomization, power analysis, pre-specified inclusion/exclusion, outlier handling, independent replication) for the experimental components are not reported.

Evidence

absence[Sections 5-9]

Randomization, blinding, power analysis, pre-specified inclusion/exclusion, outlier handling, and replication are not reported for the experimental components.

paraphrase[Section 8, Figure 4]

“Functional assays include de-O-acetylated and desialylated parasites as comparisons to untreated promastigotes.”

direct quote[Multiple sections (e.g., Section 5, 7, 8)]

“Over the past decade, we have demonstrated the presence of sialic acids... (reproduced and adapted from [...] with permission of the publishers)”

All data on Leishmania strains are referenced from prior publications by the authors and others. No new animal or human subjects were studied; the paper is a review. Thus, biological variables criteria do not apply.

Sub-criteria

demographicsN/A

sex reportedN/A

sex justifiedN/A

age weight healthN/A

housing conditionsN/A

species strain sourceN/A

Per reviewer (3) — the votes behind the verdict

N/AReviewer 1· 85% conf

The paper does not present a new experimental study where subject characteristics are a variable; it describes Leishmania strains as culture models used across previously reported experiments.

Evidence

direct quote[Section 7]

“four virulent strains of L. donovani (AG83, GE1, NS1, and NS2) and six other virulent strains K27 (L. tropica), JISH118 (L. major), LV4 (L. mexicana), LV81 (L. amazonensis), L280 (L. braziliensis), MON29 (L. infantum) demonstrate a differential distribution of SA.”

N/AReviewer 2· 100% conf

No new biological subjects were used; the paper reviews previously published data on Leishmania strains.

Evidence

paraphrase[Abstract, Sections 7-10]

“The paper's data on Leishmania strains (AG83, UR6, K27, etc.) are presented as previously published, with references cited.”

N/AReviewer 3· 95% conf

This is a review of sialobiology in Leishmania, not a study with live animal or human subjects. The work uses cultured promastigotes, but as a review summarizing prior findings, the biological variables of the original parasite strains are not fully reported here (species and strain are noted).

Evidence

direct quote[Title, Abstract, Section 1]

“A Perspective on the Emergence of Sialic Acids as Potent Determinants Affecting Leishmania Biology”

The paper synthesizes published findings. It does not describe any new experiments involving human subjects, animals, or non-public datasets. The Acknowledgements mention support from funding agencies and reagent gifts, but no ethics statement is reported. For a narrative review, this is appropriate and not_applicable.

Sub-criteria

iacuc statementN/A

informed consentN/A

irb ethics statementN/A

regulatory complianceN/A

Per reviewer (3) — the votes behind the verdict

N/AReviewer 1· 95% conf

The paper does not report new human or animal subjects research; it is a review of previously published experimental data.

Evidence

paraphrase[Title and Abstract]

“The paper is titled 'A Perspective on the Emergence of Sialic Acids as Potent Determinants Affecting Leishmania Biology' and states it assembles observations from prior work.”

N/AReviewer 2· 100% conf

This is a review article with no new human or animal subject data, tissue, or identifiable information; ethics approval is not required.

Evidence

direct quote[Title, Abstract]

“A Perspective on the Emergence of Sialic Acids as Potent Determinants Affecting Leishmania Biology”

absence[Full text]

No ethics statement is present, consistent with a review article.

N/AReviewer 3· 95% conf

The paper is a narrative review of sialic acids in Leishmania and does not present new human or animal research requiring ethics approval. Ethics statements are not reported and are not applicable.

Evidence

paraphrase[Title, Abstract]

“Paper is a perspective/review summarizing prior published work on sialic acids in Leishmania.”

The paper identifies Leishmania strains by their WHO code and species (e.g., AG83, UR6, K27). Lectins (SNA, MAA, Achatinin-H) and recombinant enzymes (esterase from H. influenzae) are named, but vendor catalog numbers and RRIDs are not provided for these key reagents. Software (Graph-Pad Prism) is named in Figure 1 legend but without version number. For a review that presents its own integrated data, complete reagent identification is expected to meet reproducibility standards, hence a 'warn' is appropriate. The 'organisms_identified' sub-criterion is adequate because strains are well-documented, but the overall reagent identification is incomplete.

Sub-criteria

mycoplasma testingNOT REPORTED

reagents identifiedINADEQUATE

organisms identifiedADEQUATE

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedINADEQUATE

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 80% conf

Key resources (Leishmania strains, lectins, recombinant enzymes) are identified, but identification is often incomplete without vendor catalog numbers or RRIDs for the biological resources used in the reviewed studies.

Evidence

direct quote[Section 7, Table 1]

“AG83 MHOM/IN/83/AG83 (L. donovani), UR6 MHOM/IN/78/UR6 (L. donovani)”

paraphrase[Sections 5 and 7]

“The paper mentions using Achatinin-H, SNA, and MAA but does not provide catalog numbers.”

direct quote[Figure 1 legend]

“Graph-Pad Prism statistics software (Graph-Pad Software Inc., San Diego, CA, USA)”

N/AReviewer 2· 100% conf

This is a review paper that does not use any biological or chemical resources for new experiments; no key resources to identify.

Evidence

absence[Full text]

No new experiments using antibodies, cell lines, or reagents are reported.

WARNReviewer 3· 80% conf

Key resources (lectins, enzymes, parasite strains, software) are partially identified but with significant gaps: antibodies/lectins are named with specificities validated, parasite strains are identified with designations, and software is identified in a figure legend, but vendor/catalog numbers, RRIDs, and full reagent details are missing.

Evidence

direct quote[Section 7, Table 1]

“AG83 MHOM/IN/83/AG83 (L. donovani) Visceral ... UR6 MHOM/IN/78/UR6 (L. donovani) Avirulent”

direct quote[Figure 1 legend]

“Results are the mean ± S.D. where, ∗ (asterisk) means P < 0.01 as compared to UR6 were performed using as Graph-Pad Prism statistics software (Graph-Pad Software Inc., San Diego, CA, USA)”

paraphrase[Sections 5, 7, 8]

“SNA, MAA, Achatinin-H, recombinant O-acetyl esterase, and sialidase from Arthrobacter ureafaciens are named without catalog numbers.”

The paper reports statistical results using P values (e.g., P < 0.01, P < 0.05) in figure legends, and names the software (Graph-Pad Prism). However, the specific tests used are not named (e.g., t-test vs. ANOVA). Test assumptions (normality, equal variance) are not mentioned. Effect sizes and confidence intervals are absent. Data are presented as bar graphs with mean ± SD (e.g., Figure 1, 2, 3), without individual data points. Exact P values are given only as thresholds (e.g., P < 0.01), not exact values. No mathematical plausibility issues are detected from the limited data reported (means ± SD from multiple experiments), but the lack of raw counts prevents thorough checking.

Sub-criteria

tests namedINADEQUATE

exact p valuesINADEQUATE

effect sizes ciNOT REPORTED

data presentationINADEQUATE

software identifiedADEQUATE

assumptions verifiedNOT REPORTED

mathematical plausibilityN/A

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 75% conf

The paper reports p-values and names statistical tests (e.g., P < 0.01 with Graph-Pad Prism), but test assumptions are not verified, exact p-values are not given (only thresholds), and effect sizes with confidence intervals are absent. Data presentation shows individual data points in bar charts, which is adequate.

Evidence

direct quote[Figure 1 legend]

“Results are the mean ± S.D. where, * (asterisk) means P < 0.01 as compared to UR6 were performed using as Graph-Pad Prism statistics software”

direct quote[Figure 1 legend]

“Graph-Pad Prism statistics software”

paraphrase[Figure 1]

“The figure shows bar charts with individual data points and error bars.”

N/AReviewer 2· 100% conf

This is a narrative review; it does not report new inferential statistics. P-values from prior studies are cited but not recomputed.

Evidence

paraphrase[Figure legends 1, 2, 4, 5, 6]

“Figure legends report P < 0.01 or P < 0.05, with the source publication cited.”

WARNReviewer 3· 80% conf

Statistical tests are named (P values, Graph-Pad Prism), and some exact P values are reported, but test assumptions are not verified, effect sizes and confidence intervals are not provided, individual data points are not shown (means ± SD), and mathematical plausibility cannot be fully assessed due to incomplete reporting of raw data.

Evidence

direct quote[Figure 1 legend]

“Results are the mean ± S.D. where, ∗ (asterisk) means P < 0.01 as compared to UR6 were performed using as Graph-Pad Prism statistics software”

direct quote[Figure 1, 2, 3 legends]

“# denotes P < 0.01 for AG83 and * denotes P < 0.05 for GE1.”

paraphrase[Figure 1, 2, 3]

“Bar graphs show mean ± SD for multiple experiments; no scatter plots or individual points are shown.”

The paper does not present any new datasets or custom code. It summarizes published results. No data availability statement is provided, which is standard for a review. All sub-criteria are not applicable.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementN/A

Per reviewer (3) — the votes behind the verdict

N/AReviewer 1· 85% conf

The paper is a narrative review/perspective that does not generate new primary data or code, so data and code availability criteria are not applicable.

Evidence

paraphrase[Title and Abstract]

“The paper is described as a perspective and review assembling observations from prior work.”

N/AReviewer 2· 100% conf

This is a review article; no new data or code were generated, so data/code availability criteria do not apply.

Evidence

absence[Full text]

No new data or code generated.

WARNReviewer 3· 85% conf

No data availability statement is present; the paper does not deposit raw data in any repository or provide accession numbers. Code sharing is not applicable as no custom code was used. The paper is a review that summarizes previously published data, but the primary data from those studies are not made available here.

Evidence

absence[Entire paper]

No data availability statement is present in the paper.

absence[Entire paper]

No repository deposit or accession numbers are provided.

The methods for sialic acid detection and functional assays are concisely described, referencing prior publications for detail but providing sufficient context. Limitations are explicitly discussed in Section 7 regarding probe specificity and labile O-acetylation. Conclusions acknowledge remaining questions and the need for in vivo validation ('the study needs to be extended in the in vivo system which remains to be explored'). Funding sources are acknowledged (CSIR, DBT, ICMR, DST), but specific grant numbers are not stated. A conflict of interest statement is present. Trial registration is not applicable. No reporting checklist (e.g., ARRIVE, which would apply to the underlying animal studies from which the data were derived) is mentioned. Given these minor reporting gaps, a 'warn' status is assigned.

Sub-criteria

funding coiINADEQUATE

trial registrationN/A

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedN/A

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (3) — the votes behind the verdict

WARNReviewer 1· 85% conf

Methods are described in considerable detail, limitations are discussed, and conclusions are generally proportional to the evidence. However, as this is not a clinical trial, trial registration is not applicable, but no reporting guideline (e.g., ARRIVE for animal studies) is referenced, and funding/COI statements are provided but are somewhat vague (funding agencies named but no grant numbers).

Evidence

direct quote[Section 7]

“First of all, there are only a few lectins which can bind only to linkage-specific 9-O-AcSA.”

direct quote[Acknowledgments]

“Council of Scientific and Industrial Research (CSIR), CSIR-IICB, Department of biotechnology and Indian council of medical research, government of India supported the paper.”

direct quote[Section 10]

“Moreover, the study needs to be extended in the in vivo system which remains to be explored.”

PASSReviewer 2· 85% conf

The review is transparent: methods from prior studies are cited, limitations are discussed, conclusions are proportionate, and funding/COI are declared.

Evidence

direct quote[Section 7]

“there are a few limitations in this field of work due to lack of reagents/probes.”

direct quote[Section 10]

“we hypothesize this 9-O-acetylated sialoglycotope to be one of the many existing markers of virulence in leishmania biology.”

direct quote[Acknowledgments]

“The authors do not have a commercial or other association that might pose a conflict of interest.”

WARNReviewer 3· 85% conf

Methods are described in moderate detail (lectin binding, flow cytometry, HPLC, GC/MS, infection assays), but trial registration and reporting guidelines are not applicable. Limitations are discussed, conclusions are generally proportional to the evidence, and funding/COI are disclosed. However, the paper does not follow any formal review reporting guideline, and methods for the review process itself (search strategy, selection criteria) are absent.

Evidence

direct quote[Section 7, paragraph 6; Section 10]

“First of all, there are only a few lectins which can bind only to linkage-specific 9- O- AcSA.”

direct quote[Acknowledgments, last paragraph]

“The authors do not have a commercial or other association that might pose a conflict of interest.”

absence[Entire paper]

No reporting guideline (e.g., PRISMA) is followed for the review component.

19 copyedit issues flagged: mostly consistency, clarity, other.

Reproducibility

1 data/code link checked; 1 live.

Αlpha¹ Rigor Action ItemsFinal pass before journal submission

As a published paper, this perspective is robust in its scientific premise but has reporting gaps that a critical reader should weigh. The missing resource identifiers (catalog numbers), incomplete statistical reporting (threshold p-values, no effect sizes), and absence of review methodology (search strategy, selection criteria) would make independent verification of the synthesized findings difficult. An erratum could provide missing reagent details and clarify the statistical analyses.

1.
HIGHreporting
Describe the review methodology in a new section, including search strategy (databases, search terms, date range), inclusion/exclusion criteria for selecting studies, and methods of data synthesis.
A narrative review without any described methodology is a significant transparency gap; readers cannot assess the comprehensiveness or bias of the literature selection.
2.
HIGHrigor
Add vendor catalog numbers or RRIDs for all key reagents: lectins (Achatinin-H, SNA, MAA), recombinant esterase from H. influenzae, and sialidase from Arthrobacter ureafaciens.
Without catalog numbers or RRIDs, independent researchers cannot identify or acquire the exact reagents used, undermining reproducibility.
3.
HIGHstatistics
State the specific statistical test used for each p-value (e.g., unpaired two-tailed t-test, one-way ANOVA with post-hoc test) directly in each figure legend.
Naming only the software package does not inform the reader which test was applied, making the analysis unverifiable.
4.
HIGHstatistics
Report exact p-values (e.g., P = 0.003) instead of thresholds (P < 0.01) for all statistical comparisons.
Threshold-only p-values do not allow readers to assess the strength of evidence; exact p-values are standard for rigorous reporting.
5.
HIGHstatistics
Include effect sizes (e.g., mean difference, Cohen's d, or fold-change) and 95% confidence intervals for the key comparisons shown in Figures 1, 4, 5, and 6.
P-values alone do not convey the magnitude or precision of effects, which are essential for interpreting biological significance.
6.
HIGHreporting
Include specific grant numbers for each funding agency (CSIR, DBT, ICMR, DST) in the Acknowledgments.
Grant numbers are required by many funding agencies and increase transparency in funding attribution.
7.
MEDIUMstatistics
Add individual data points (scatter plots or dot plots) to the bar graphs in Figures 1-3 to show data distribution and variability.
Bar graphs with only mean ± SD can obscure sample size, outliers, and distribution shape; individual points allow readers to assess data quality.
8.
MEDIUMstatistics
State the version number of Graph-Pad Prism used for statistical analyses.
Software version can affect computational outputs; version identification is a reproducibility standard.
9.
MEDIUMstatistics
Describe how test assumptions (normality, equal variance) were verified for each statistical test, and which alternative tests were used if assumptions were violated.
Without assumption verification, the validity of parametric tests cannot be assessed by the reader.
10.
MEDIUMreporting
Add a data availability statement specifying that no new data were generated for this review, and that all data are from previously published studies as cited.
Even for reviews, a data availability statement clarifies data provenance and aligns with many journal policies.
11.
MEDIUMreporting
Consider citing a reporting guideline for narrative reviews (e.g., the Scale for the Assessment of Narrative Review Articles—SANRA) to improve methodological transparency.
Reference to a reporting guideline helps ensure completeness of the review and is increasingly expected by journals.
12.
MEDIUMreporting
Provide a brief statement about whether blinding or randomization were used in the original experiments from which data are drawn, or state that this information is not available from the primary publications.
Transparency about the limitations of the underlying primary studies helps readers assess the strength of the evidence synthesized.
13.
LOWcopyedit
Correct typographical errors: 'consequencess' to 'consequences' (Section 10), 'due their' to 'due to their' (Section 6, paragraph 2), 'Ne5Gc' to 'Neu5Gc' (Section 7), 'asterix' to 'asterisk' (Figure 2 caption), 's imilar finding ()' to 'similar finding' (Section 7), 'performed using as' to 'performed using' (Figure 1 legend).
Typos and grammatical errors detract from the overall quality and clarity of the manuscript.
14.
LOWcopyedit
Standardize taxonomic abbreviations: change 'Leishmania sp.' to 'Leishmania spp.' when referring to multiple species (Figure 1 caption, Table 1).
Inconsistent use of taxonomic abbreviations is a minor but noticeable error in a biology paper.
15.
LOWcopyedit
Add a comma after 'amastigotes' in the Abstract sentence: 'promastigotes and amastigotes, having adaptations for subverting host immune responses'.
The missing comma creates a grammatical run-on that reduces clarity.

Full text (42,548 chars)Analyzed: Jul 6, 2026

Αlpha¹ assesses methodological rigor, not the importance of the findings. See how we calibrate →